CD38 and AL amyloidosis: Early non-clinical and initial human data from studies involving patients with multiple myeloma have shown mezagitamab to have a favorable safety profile and promising pharmacodynamic effects, particularly in the reduction of CD38-expressing target cells [186, 187].